ARAV Aravive Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARAV

Price (delayed)

$0.1359

Market cap

$10M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.52

Enterprise value

$1.48M

Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive is based in Houston, Texas and received a Product Development Award ...

Highlights
The company's EPS has surged by 78% YoY and by 60% QoQ
The company's net income rose by 48% QoQ and by 34% YoY
The company's equity has surged by 109% QoQ but it has shrunk by 89% YoY
The company's quick ratio fell by 27% YoY and by 23% QoQ
The company's revenue fell by 24% QoQ and by 19% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://aravive.com
Peers: OMGA

Key stats

What are the main financial stats of ARAV
Market
Shares outstanding
73.56M
Market cap
$10M
Enterprise value
$1.48M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.88
Price to sales (P/S)
1.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.21
Earnings
Revenue
$7M
EBIT
-$39.85M
EBITDA
-$38.97M
Free cash flow
-$59.45M
Per share
EPS
-$0.52
Free cash flow per share
-$0.78
Book value per share
$0.02
Revenue per share
$0.09
TBVPS
$0.17
Balance sheet
Total assets
$13.05M
Total liabilities
$11.35M
Debt
$2.43M
Equity
$1.7M
Working capital
-$215,000
Liquidity
Debt to equity
1.43
Current ratio
0.98
Quick ratio
1.12
Net debt/EBITDA
0.22
Margins
EBITDA margin
-557.1%
Gross margin
100%
Net margin
-569.6%
Operating margin
-847.4%
Efficiency
Return on assets
-110.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-1,217.8%
Return on sales
-569.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARAV stock price

How has the Aravive stock price performed over time
Intraday
-6.92%
1 week
-7.49%
1 month
2.03%
1 year
-90.15%
YTD
-89.7%
QTD
2.95%

Financial performance

How have Aravive's revenue and profit performed over time
Revenue
$7M
Gross profit
$7M
Operating income
-$59.28M
Net income
-$39.85M
Gross margin
100%
Net margin
-569.6%
The company's net income rose by 48% QoQ and by 34% YoY
The company's net margin rose by 32% QoQ and by 18% YoY
The company's revenue fell by 24% QoQ and by 19% YoY
ARAV's gross profit is down by 24% QoQ and by 19% YoY

Growth

What is Aravive's growth rate over time

Valuation

What is Aravive stock price valuation
P/E
N/A
P/B
5.88
P/S
1.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.21
The company's EPS has surged by 78% YoY and by 60% QoQ
The company's equity has surged by 109% QoQ but it has shrunk by 89% YoY
The price to sales (P/S) is 88% less than the 5-year quarterly average of 13.2 and 81% less than the last 4 quarters average of 8.2
The company's revenue fell by 24% QoQ and by 19% YoY

Efficiency

How efficient is Aravive business performance
Aravive's ROA has increased by 38% from the previous quarter but it has decreased by 10% YoY
The company's return on sales rose by 32% QoQ and by 18% YoY

Dividends

What is ARAV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARAV.

Financial health

How did Aravive financials performed over time
Aravive's total assets is 15% higher than its total liabilities
ARAV's total liabilities has dropped by 75% since the previous quarter and by 58% year-on-year
Aravive's total assets has shrunk by 69% YoY and by 49% QoQ
The company's debt is 43% higher than its equity
The company's equity has surged by 109% QoQ but it has shrunk by 89% YoY
The company's debt fell by 48% YoY and by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.